Venus Remedies has rallied 6% at Rs 219 after the company said it has launched a nanotechnology based ‘ready-to-use’ single vial Docetaxel in the domestic market under the brand name “TAXEDOL”.
“The company is hopeful of capturing significant share in Rs 1,500 crore Indian cancer drug industry, which is speculated to show a steady growth over the coming few years,” Venus Remedies said in a filing. The medicine is a single vial formulation available in three strengths, it added.
The stock opened at Rs 209 and touched high of Rs 222 on the National Stock Exchange. A combined 101,638 shares have changed hands on the counter so far, against an average sub 50,000 shares that were traded in past ten trading days.
